NCT03375463View on ClinicalTrials.gov

A Study of Tirzepatide (LY3298176) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

December 27, 2018

Study Completion Date

December 27, 2018

Conditions

Healthy

Interventions

DRUG

Tirzepatide

Administered SC

DRUG

Tirzepatide

Administered IV

DRUG

Placebo

Administered SC

DRUG

Tirzepatide

Administered IV

Trial Locations (1)

75247

Covance, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT03375463 - A Study of Tirzepatide (LY3298176) in Healthy Participants | Biotech Hunter | Biotech Hunter